AUPH — AURINIA PHARMACEUTICALS INC
Public company
InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.
Sourced from SEC EDGAR public filings
Why are billionaires buying AUPH?
Built from public SEC filings and public economic data. Not a recommendation.
Why? — Evidence & Confidence ▾
Of 4 tracked investors who changed their AUPH position last quarter, 3 bought and 1 sold (75% buy-side). Macro conditions are a headwind for this sector (Macro Tailwind 38/100 in a Expansion regime).
- +3 tracked investors added or increased positions last quarter (Paul Tudor Jones, Steve Cohen, Ken Griffin)
- +4 tracked investors reported holding AUPH at their latest filing
- −1 tracked investor reduced or exited last quarter (1 reduced, 0 sold out)
- −Current Expansion regime has historically been a headwind for this sector (Macro Tailwind 38/100)
- −13F data is disclosed up to 45 days after quarter end — positions may have changed since
- · 13F disclosure lag (up to 45 days)
- · Tracked investors are a sample, not the whole market
- · Sector regime fit is a historical average, not a guarantee
Every InvestorLens score shows its evidence — including what argues against it. Model conviction-v1 · generated 11/22/2026.
About AURINIA PHARMACEUTICALS INC (AUPH)
AURINIA PHARMACEUTICALS INC (AUPH) appears in the most recent 13F filings of 4 tracked institutional investors. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $17M. Across recent filings, tracked investors recorded 7 new positions, 7 increased, 7 reduced, and 4 exited. All data sourced from SEC 13F filings.
Based on recent institutional activity in AUPH
How many top investors track AUPH
A small number of top investors own this.
AUPH Ownership Composition
How AURINIA PHARMACEUTICALS INC is held across tracked investor types, based on reported 13F positions.
- Multi-Strategy / Quant96.4%
- Macro3.6%
Tracked investors currently reporting AUPH
- Ken GriffinSep 30, 2026Citadel AdvisorsShares1.1MValue$17.1M% Portfolio0.00%
- Izzy EnglanderSep 30, 2026Millennium ManagementShares16.9KValue$273.6K% Portfolio0.00%
- Steve CohenSep 30, 2026Point72 Asset ManagementShares223.9KValue$3.6M% Portfolio0.00%
- Paul Tudor JonesSep 30, 2026Tudor Investment CorpShares47.9KValue$775K% Portfolio0.00%
Recent activity
- $775KNov 16, 2026
- Reduced$273.6K(-93.08%)Nov 16, 2026
- New$3.6MNov 16, 2026
- Increased$17.1M(126.48%)Nov 16, 2026
- Increased$427.5K(395.54%)Nov 14, 2024
- Increased$785K(49.89%)Feb 14, 2025
- Reduced$181.5K(-74.18%)May 15, 2025
- Increased$1.4M(628.72%)Aug 14, 2025
- Increased$11.8M(634.10%)Feb 17, 2026
- Reduced$1.7M(-84.13%)May 15, 2026
- Increased$4.1M(108.50%)Aug 14, 2026
- Reduced$8.1M(-11.48%)Nov 14, 2024
- Reduced$2.9M(-49.37%)May 15, 2025
- Reduced$2.7M(-9.76%)Aug 14, 2025
- Sold$0(-100.00%)Nov 14, 2025
- Increased$7.9M(14.39%)Aug 14, 2026
- New$7.6MFeb 14, 2025
- Sold$0(-100.00%)Jul 21, 2025
- Sold$0(-100.00%)Aug 14, 2024
- $728.9KDec 9, 2025
- Reduced$1.5M(-10.51%)May 15, 2026
- Sold$0(-100.00%)Aug 14, 2026
- New$7.1MAug 14, 2024
- $94.1KMay 15, 2024
- $74.9KMay 15, 2024
Frequently asked questions
- How many institutional investors hold AUPH?
- 4 tracked institutional investors disclosed a position in AUPH (AURINIA PHARMACEUTICALS INC) in their most recent 13F filing.
- Who is the largest institutional holder of AUPH?
- Ken Griffin, Citadel Advisors, holds the largest disclosed position in AUPH, valued at $17M.
- Did institutional ownership of AUPH increase or decrease?
- Across recent 13F filings, tracked investors recorded 7 new positions, 7 increased, 7 reduced, and 4 fully exited AUPH.
- Where does this AUPH ownership data come from?
- SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.